CAMP CAMP4 Therapeutics Corporation
USHealthcareAs of 2026-07-02
Why CAMP matters now
CAMP4 Therapeutics Corporation (CAMP) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.43 with +2.07% on the session and $94.1M in market capitalization; recent performance reads 1-month -0.48% and YTD -32.63%.
The latest financial table shown here is Q1 2026, with revenue of $1.3M, net income of $-18.3M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -29.9%.
The latest indexable market news headline is "CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.50; recent insider activity includes Nashat Amir filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.74
P/S
22.30
EV/EBITDA
0.18
DCF Value
$2.91
FCF Yield
-29.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.2%
Operating Margin
-1322.6%
Net Margin
-2193.7%
ROE
-194.7%
ROA
-81.8%
ROIC
-58.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.3M | $-18.3M | $-0.32 |
| Q4 2025 | $348.0K | $-40.3M | $-0.78 |
| FY 2025 | $3.5M | $-80.4M | $-2.65 |
| Q3 2025 | $795.0K | $-15.1M | $-0.55 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.50
Target (Median)
$6.50
Target Range
$6.50 - $6.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.08
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.